Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia

Back to Search
Print
Bookmark Trial

NCT00037596

Last updated date
Back to Search
Print
Bookmark Trial
FOR MORE INFORMATION
Contact
1-800-718-1021
[email protected]
Related Links

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

By phone

Pfizer Clinical Trials Contact Center

1-800-718-1021

By email

Contact

[email protected]

Call Now

Eligibility Criteria
condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Acute Myeloid Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18 + years
Inclusion Criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Morphologic diagnosis of AML from bone marrow aspirate and biopsy

- Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33+, based on local laboratory criteria

- Age 18 years or older for relapsed or refractory patients for Phase I of this study

Exclusion Criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details


- Patients with de novo AML of the M3 subtype


- AML following an antecedent hematologic disorder (myelodysplasia or
myeloproliferation) of > 2 months duration


- AML secondary to exposure to chemotherapy or radiation

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

Call Now

TRY A NEW SEARCH

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

Advanced Search

Based on your search, you may also be interested in

Acute Myeloid LeukemiaStudy Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia NCT00037583
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia NCT00037596
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaStudy Evaluating Mylotarg (Gemtuzumab Ozogamicin) in Usual Care NCT00161668
  1. Tucson, Arizona
  2. Berkely, California
  3. Burbank, California
  4. Concord, California
  5. Loma Linda, California
  6. Los Angeles, California
  7. San Francisco, California
  8. Sylmar, California
  9. Denver, Colorado
  10. Boynton Beach, Florida
  11. Plantation, Florida
  12. Stuart, Florida
  13. Tamarac, Florida
  14. Chicago, Illinois
  15. Chicago, Illinois
  16. Chicago, Illinois
  17. Chicago, Illinois
  18. Indianapolis, Indiana
  19. Iowa City, Iowa
  20. Lexington, Kentucky
  21. Louisville, Kentucky
  22. Shrevport, Louisiana
  23. Ann Arbor, Michigan
  24. Grand Rapids, Michigan
  25. Kalamazoo, Michigan
  26. Kalamazoo, Michigan
  27. Columbia, Missouri
  28. St. Louis, Missouri
  29. Neptune, New Jersey
  30. Albuquerque, New Mexico
  31. Bronx, New York
  32. Buffalo, New York
  33. New Hyde Park, New York
  34. New York, New York
  35. New York, New York
  36. Valhalla, New York
  37. Durham, North Carolina
  38. Winston-Salem, North Carolina
  39. Bismarck, North Dakota
  40. Akron, Ohio
  41. Canton, Ohio
  42. Cincinnati, Ohio
  43. Cleveland, Ohio
  44. Oklahoma City, Oklahoma
  45. Portland, Oregon
  46. Hershey, Pennsylvania
  47. Philadelphia, Pennsylvania
  48. Philadelphia, Pennsylvania
  49. Pittsburgh, Pennsylvania
  50. Memphis, Tennessee
  51. Nashville, Tennessee
  52. Nashville, Tennessee
  53. Houston, Texas
  54. Temple, Texas
  55. Arlington, Virginia
  56. Richmond, Virginia
  57. Charleston, West Virginia
  58. Morgantown, West Virginia
  59. Appleton, Wisconsin
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Acute Myeloid LeukemiaA Study To Evaluate PF-04449913 With Chemotherapy In Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome NCT01546038
  1. Birmingham, Alabama
  2. Birmingham, Alabama
  3. Birmingham, Alabama
  4. La Jolla, California
  5. La Jolla, California
  6. La Jolla, California
  7. Los Angeles, California
  8. Los Angeles, California
  9. Los Angeles, California
  10. Los Angeles, California
  11. Los Angeles, California
  12. Los Angeles, California
  13. Los Angeles, California
  14. Los Angeles, California
  15. San Diego, California
  16. Aurora, Colorado
  17. Aurora, Colorado
  18. Tampa, Florida
  19. Atlanta, Georgia
  20. Atlanta, Georgia
  21. Atlanta, Georgia
  22. Atlanta, Georgia
  23. Chicago, Illinois
  24. Chicago, Illinois
  25. Chicago, Illinois
  26. Chicago, Illinois
  27. Chicago, Illinois
  28. Fairway, Kansas
  29. Kansas City, Kansas
  30. Westwood, Kansas
  31. Baltimore, Maryland
  32. Boston, Massachusetts
  33. Boston, Massachusetts
  34. Boston, Massachusetts
  35. Boston, Massachusetts
  36. Ann Arbor, Michigan
  37. Ann Arbor, Michigan
  38. Creve Coeur, Missouri
  39. Saint Louis, Missouri
  40. Saint Louis, Missouri
  41. Saint Louis, Missouri
  42. Saint Louis, Missouri
  43. Hackensack, New Jersey
  44. Hackensack, New Jersey
  45. Buffalo, New York
  46. Cleveland, Ohio
  47. Nashville, Tennessee
  48. Nashville, Tennessee
  49. Nashville, Tennessee
  50. Houston, Texas
  51. Seattle, Washington
  52. Seattle, Washington
  53. Hamilton, Ontario
  54. Greenfield Park, Quebec
  55. Ulm, Baden-wuerttemberg
  56. Frankfurt am Main, Hessen
  57. Hannover, Lower Saxony
  58. Berlin,
  59. Berlin,
  60. Hamburg,
  61. Kiel,
  62. Magdeburg,
  63. Mainz,
  64. Muenster,
  65. Ulm,
  66. Bologna, Province OF Bologna
  67. Milano,
  68. Rome,
  69. Torino,
  70. Udine,
  71. Gdansk, Pomorskie
  72. Lodz,
  73. Wroclaw,
  74. Sevilla, Andalucia
  75. Badalona, Barcelona
  76. Barcelona,
  77. Barcelona,
  78. Barcelona,
  79. Barcelona,
  80. Madrid,
  81. Valencia,
ALL GENDERS
18 Years+
years
MULTIPLE SITES
Advanced Information
Descriptive Information
Brief Title  ICMJE Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
Official Title  ICMJE A Dose Ranging Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) Given in Combination With Cytarabine in Relapsed or Refractory Patients and Alder De Novo Patients With Acute Myeloid Leukemia.
Brief Summary The primary objectives are a) to establish the maximum tolerated dose of gemtuzumab ozogamicin in combination with cytarabine and b) to assess the safety of gemtuzumab ozogamicin when given concurrently with cytarabine.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Primary Purpose: Treatment
Condition  ICMJE Acute Myeloid Leukemia
Intervention  ICMJE
  • Drug: Gemtuzumab Ozogamicin
  • Drug: cytarabine.
Study Arms  ICMJE Not Provided
Publications * Hibma J, Knight B. Population Pharmacokinetic Modeling of Gemtuzumab Ozogamicin in Adult Patients with Acute Myeloid Leukemia. Clin Pharmacokinet. 2019 Mar;58(3):335-347. doi: 10.1007/s40262-018-0699-5.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Completed
Enrollment  ICMJE Not Provided
Original Enrollment  ICMJE Not Provided
Actual Study Completion Date  ICMJE April 2003
Actual Primary Completion Date April 2003   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Morphologic diagnosis of AML from bone marrow aspirate and biopsy
  • Flow cytometry, performed at the study site, must demonstrate that the patient has AML that is CD33+, based on local laboratory criteria
  • Age 18 years or older for relapsed or refractory patients for Phase I of this study

Exclusion Criteria:

  • Patients with de novo AML of the M3 subtype
  • AML following an antecedent hematologic disorder (myelodysplasia or myeloproliferation) of > 2 months duration
  • AML secondary to exposure to chemotherapy or radiation
Sex/Gender  ICMJE
Sexes Eligible for Study:All
Ages  ICMJE 18 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE Contact information is only displayed when the study is recruiting subjects
Listed Location Countries  ICMJE Not Provided
Removed Location Countries United States
 
Administrative Information
NCT Number  ICMJE NCT00037596
Other Study ID Numbers  ICMJE 0903B1-205
Has Data Monitoring Committee Not Provided
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement  ICMJE Not Provided
Responsible Party Not Provided
Study Sponsor  ICMJE Wyeth is now a wholly owned subsidiary of Pfizer
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Study Director:Medical Monitor, MDWyeth is now a wholly owned subsidiary of Pfizer
PRS Account Wyeth is now a wholly owned subsidiary of Pfizer
Verification Date February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP